Senate FDA Appropriation Includes $2M For CBD Enforcement Discretion Policy
Executive Summary
Instruction in Appropriations Committee report on FY 2020 spending bill garners support from some stakeholders while others say setting a safe level of CBD's use in non-drug products should come first. Senate appropriators endorses FDA policy that regulations allowing sales of CBD non-drug products "not discourage the development of new drugs."
You may also be interested in...
$2m For CBD Policy In FDA Budget, But No Directive On Setting Safe Level
Both Senate and House reports on FDA FY 2020 appropriation include requests for agency’s research, policy evaluation, market surveillance, issuance of an enforcement discretion policy and appropriate regulatory activities related to regulated products that contain hemp-derived CBD. House report, though, expresses stronger concern about exploding sales of potentially unsafe CBD supplements.
HBW Market News: CHPA Petitions For CBD Reg, PEW Urges Stronger Supplement Oversight
AHPA releases guidance for tea and infusion products on regulatory and liability implications as a result of increasing Prop 65 lawsuits; CHPA files citizen petition urging FDA to act on a CBD pathway; PEW pushes for stronger supplement oversight; and more.
NJ Senators Tell Congress 'Complicated Legal Framework' Hurts CBD Firms
NJ senators say although FDA deems dietary ingredients and food additives with CBD as unlawful, in the past three years more than 1,500 CBD products have come to market “without a clear approach for regulation or any plan from the FDA to balance consumer access and protect consumer health.”